TRxADE Health (NASDAQ: MEDS), a pharmaceutical exchange platform provider, previously entered a binding letter of intent (“LOI”) to acquire Superlatus Inc., a U.S.-based holding company of food products and distribution capabilities. Subject to customary conditions, the merger was approved by the board of directors of both companies and is expected to close in the late third quarter or early fourth quarter of 2023. Superlatus today announced the expansion of its management team, which includes the appointment of Dr. Eugenio Bortone as its president and COO and Tim Alford, currently serving as interim CEO, who will transition into the position of chief commercialization officer (“CCO”). “We are proud of our newly appointed management team members who are highly skilled and have deep expertise in the food and agribusiness sector,” said Superlatus’ interim CEO Tim Alford. “Working closely with our board of directors, these talented and experienced management team members will work to bring products from tech to implementation. Leveraging the knowledge of these accomplished individuals will be important as we close on potential acquisitions, implement on our aggressive acquisition strategy, and unlock the synergies of the various acquired entities to grow our revenues and maximize our market share in this dynamic and competitive industry.”
To view the full press release, visit https://ibn.fm/633Xe
About TRxADE Health Inc.
TRxADE Health is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The company operates the TRxADE drug procurement marketplace serving a total of 14,500+ members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient-centric telehealth services. For more information on TRxADE Health, visit the company’s IR website at investors.trxadegroup.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork